Feasibility of Long-term, High-dose Stimulant for Methamphetamine Use Disorder
Key facts
- Who runs it
- Centre hospitalier de l'Université de Montréal (CHUM)
- Where
- Canada1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 80 people, planned
- Started
- 18 Jul 2025
- Expected to end
- Dec 2027
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- LDX-01 plus TAU
- Placebo plus TAU
- Record updated
- 23 February 2026
Who can take part
- Age
- 18 years to 55 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 24 criteriaShow less
Who can take part
- Between 18 and 55 years of age at enrollment in the parent ASCME trial
- Diagnosed with a moderate to severe MUD as defined by the DSM-5 criteria
- Enrolled in the parent ASCME trial and completed the study up to and including the end of study visit at Week 20, Day 1
- Interested in avoiding relapse, decreasing methamphetamine use, or abstaining from methamphetamine use
- Presence of ongoing substance use, craving, or significant risk of relapse that according to the study physician, warrants extended treatment for MUD
- If female:; Be of non-childbearing potential, defined as (i) postmenopausal (12 months of spontaneous amenorrhea and ≥ 45 years of age); or (ii) documented surgically sterilized (i.e., tubal ligation, hysterectomy, or bilateral oophorectomy); or; Be of childbearing potential, have a negative pregnancy test at screening, and agree to use an acceptable method of birth control throughout the study
- Willing to be randomized to one of 2 study arms and followed for the duration of the trial
- Able to start the study intervention within 28 days after completing the ASCME main trial (study no. CRISM-002)
- Able to provide informed consent
- Willing to comply with study procedures
- Able to communicate in English or French
Who cannot take part
- Planned extended absence during the study period (e.g., pending legal action, surgery, incarceration, inpatient residential program) in the opinion of the study physician that might prevent completion of the study
- Use of an investigational drug for stimulant use disorder during the 30 days before screening, confirmed via self-report or pharmacy records; excluding the use of study medication in the parent ASCME trial
- Use of prescribed amphetamine-type medication or medication for the treatment of stimulant use disorder (e.g., methylphenidate, modafinil, bupropion, or mirtazapine) in the 4 weeks before screening
- Current or anticipated need for treatment with any medication that may interact with LDX-01 (e.g., monoamine oxidase inhibitors [MAOIs]) used currently or within the past 14 days and that would preclude study participant at the discretion of the study physician
- Symptomatic or advanced cardiovascular disease (e.g., advanced arteriosclerosis), moderate hypertension; confirmed current hyperthyroidism; known hypersensitivity or idiosyncrasy to the sympathomimetic amines or glaucoma or any disabling, severe, or unstable medical condition (including electrolyte disturbances) that, in the opinion of the study physician, precludes safe participation or the ability to provide fully informed consent
- Any severe or unstable co-morbid substance use disorder that, in the opinion of the study physician, precludes safe participation in the study
- Participants with Opioid Use Disorder (OUD) who have been on Opioid Agonist Treatment (OAT) for <12 weeks, and not yet at stabilization dose, or at stabilization dose <4 weeks
- Current or a history of any serious psychiatric disorder (e.g., bipolar disorder, pre-existing psychosis, schizophrenia) that, in the opinion of the study physician, precludes safe participation in the study
- History of a SAE, hypersensitivity or known allergic reaction to LDX-01 or other amphetamine drugs, or hypersensitivity to the sympathomimetic amines
- ECG measurement (Bazett method for the correction of QT interval) that indicates a prolonged QTc interval (≥460 milliseconds for females and ≥450 milliseconds for males) at screening
- Pregnant, nursing, or planning to become pregnant during the study period
- Any SAEs related to the study product in the parent trial phase that, in the opinion of the study physician, precludes safe participation in the extension study
- Any compliance issues related to the study product and/or study procedures during the parent trial phase that, in the opinion of the study physician, precludes safe participation in the extension study
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 55 years old?
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Methamphetamine use disorder (MUD) is becoming an increasing public health concern in Canada. While the evidence on the efficacy and safety of prescription psychostimulants for the treatment of MUD is promising, the knowledge on the maintenance therapy using stimulant agonist therapy is scarce and needs further investigation, especially in terms of long-term retention in treatment.
Read full original descriptionShow less
The goal of this clinical trial is to evaluate the feasibility of a long-term (25 weeks) administration of high-dose stimulant agonist therapy, using Lisdexamfetamine (LDX-01) on top of treatment-as-usual (TAU), in a population of people with moderate to severe MUD, as measured by study retention, treatment retention, treatment adherence and satisfaction compared against a placebo group.
Participants will be placed randomly into one of two groups:
1. TAU and high-dose LDX-01 2. TAU and placebo
The 2 groups in the trial
- LDX-01 + TAUTreatment being tested
Participants will receive TAU at the clinic as well as once daily over-encapsulated LDX-01 orally for 25 weeks.
Treatment: LDX-01 plus TAU
- Placebo + TAUPlacebo, for comparison
Participants will receive TAU at the clinic as well as once daily LDX-01-matched placebo orally for 25 weeks.
Treatment: Placebo plus TAU
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Exploring Feasibility and Acceptability of Prolonged Administration of High-Dose Stimulants in People With Methamphetamine Use Disorder: An Extension of a Randomized, Placebo-Controlled Trial
- Fit questions
- Built from NCT06788587, who can take part
- Record updated
- 23 February 2026